GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G1 Therapeutics Inc (NAS:GTHX) » Definitions » Price-to-Free-Cash-Flow
中文

G1 Therapeutics (G1 Therapeutics) Price-to-Free-Cash-Flow

: N/A (As of Today)
View and export this data going back to 2017. Start your Free Trial

As of today (2024-04-24), G1 Therapeutics's share price is $4.045. G1 Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.78. Hence, G1 Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for G1 Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

GTHX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

G1 Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.25. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.78.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 30.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 13.20% per year.

During the past 9 years, G1 Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 30.50% per year. The lowest was -48.90% per year. And the median was -7.30% per year.


G1 Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for G1 Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G1 Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - - - -

G1 Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, G1 Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


G1 Therapeutics Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, G1 Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where G1 Therapeutics's Price-to-Free-Cash-Flow falls into.



G1 Therapeutics Price-to-Free-Cash-Flow Calculation

G1 Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=4.045/-0.783
=N/A

G1 Therapeutics's Share Price of today is $4.045.
G1 Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.78.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

G1 Therapeutics  (NAS:GTHX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


G1 Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of G1 Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


G1 Therapeutics (G1 Therapeutics) Business Description

Traded in Other Exchanges
Address
700 Park Offices Drive, Suite 200, Research Triangle Park, NC, USA, 27709
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies.
Executives
John V. Umstead officer: Chief Financial Officer C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Rajesh Malik officer: Chief Medical Officer 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Mark Avagliano officer: Chief Business Officer 79 T.W. ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Terry L Murdock officer: Chief Operating Officer
Bailey John E. (jack) Jr. director, officer: President and CEO C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Andrew Perry officer: Chief Commercial Officer C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Mark A. Velleca director, officer: President and CEO 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Monica R. Thomas officer: General Counsel 700 PARK OFFICES, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Jennifer K. Moses officer: CFO 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
James S. Hanson officer: General Counsel 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Norman Sharpless director 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 22709
Jacks Lee director 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Seth Rudnick director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS, MISSISSAUGA A6 L5N 0E4
Alicia Secor director 33 HAYDEN AVE., LEXINGTON MA 02421
Soma Gupta officer: Chief Commercial Officer C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709

G1 Therapeutics (G1 Therapeutics) Headlines

From GuruFocus

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Stock market mentor Stock market mentor 02-01-2023